Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira-Enabled Non-RNAi Drugs Acquired by Spectrum Pharmaceuticals


Tekmira Pharmaceuticals this week announced that Talon Therapeutics, which licensed certain of the company’s legacy, non-RNAi drug candidates, will be acquired by Spectrum Pharmaceuticals.

According to Tekmira, Spectrum has stated that it intends to launch one of those drugs, the liposome-formulated chemotherapeutic Marqibo, later this year through its own sales force. Tekmira received a $1 million milestone payment last year from Talon related to the US Food and Drug Administration approval of Marqibo, and stands to receive royalties from Spectrum on the product’s sales.

"The future sales of Marqibo represent a recurring revenue stream for Tekmira,” Tekmira President and CEO Mark Murray said in a statement.

Through its acquisition of Talon, Spectrum has also picked up two other drug candidates, one in phase I testing and one still preclinical, for which Tekmira is eligible for milestones and royalties.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.